<DOC>
	<DOCNO>NCT01508988</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability ascend single dos ONO-9054 administer single drop healthy adult subject . The secondary objective characterize pharmacokinetic ( PK ) profile ONO-9054 metabolite plasma evaluate pharmacodynamic ( PD ) profile .</brief_summary>
	<brief_title>Single Dose Escalation Study ONO-9054 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Healthy male female subject , age 1864 inclusive Body mass index ( BMI ) 1935 kg/m2 ( inclusive ) IOP measurement oculus uterque ( OU , eye ) &lt; 21 mm Hg ( inclusive ) screen Day 1 Best correct visual acuity ( BCVA ) 20/30 good ( Snellen Equivalent ) screen visit Day 1 Any history severe ocular trauma either eye time Any history previous intraocular ocular laser surgery within past 3 month refractive surgery procedure within past 6 month screen visit either eye Current chronic history ocular infection within past 3 month screen visit either eye OR ongoing recurrent ocular inflammation either eye At ophthalmic investigator 's discretion , subject history significant ocular condition either eye would contraindicate use study medication , might affect study conduct , interpretation study result Use nondiagnostic topical ophthalmic solution except sponsorrecommended tear substitute admission study unit duration study History clinically significant drug food allergy , positive HIV , hepatitis B C screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ONO-9054</keyword>
	<keyword>adult healthy volunteer</keyword>
	<keyword>single dose</keyword>
	<keyword>phase 1</keyword>
</DOC>